SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
Zhenyu Xu, Chief Scientific Officer of SOPHiA GENETICS SA, sold 7,394 ordinary shares on October 5, 2026, at a weighted average price of $8.1248 per share. The shares were sold in multiple open-market transactions to satisfy tax withholding obligations arising from restricted stock unit vesting on October 2 and 3, 2026. The sales were made under a pre-established Rule 10b5-1(c) plan and did not represent discretionary trades. Xu reported direct holdings of 545,493 shares after the sale; transaction prices ranged from $7.99 to $8.30 per share, inclusive.
SOPHiA GENETICS SA Chief Executive Officer and director Ross Muken sold 9,838 ordinary shares on October 5, 2026, at a weighted average price of $8.1288 per share, leaving him with 660,391 shares held directly. The shares were sold to satisfy tax withholding obligations arising from restricted stock units vesting on October 2 and 3, 2026, under a pre-established Rule 10b5-1(c) trading plan; the footnote says the sales were not discretionary. Sale prices ranged from $7.91 to $8.34 per share.
SOPHiA GENETICS SA (SOPH) officer Zhenyu Xu reported a planned sale of 19,394 common shares, with an aggregate market value of $156,509.58 and an approximate sale date of October 5, 2026. The notice also lists earlier sales identified as “10b5-1 Sales,” including 4,000 shares for $31,537.60 on September 14, 2026, and 10,000 shares for $89,096.00 on August 27, 2026. It lists 85,127,825 shares outstanding.
SOPHiA GENETICS SA (SOPH) officer Daan Guido Maria Van Well reported a proposed sale of 6,168 common shares, with an aggregate market value of $49,775.76 and an approximate sale date of October 5, 2026, through Morgan Stanley Smith Barney LLC on NASDAQ. The shares were acquired upon vesting of restricted stock units on October 2 and October 3, 2026. The notice also lists a September 11, 2026 sale of 6,168 common shares for gross proceeds of $47,088.98 as 10b5-1 sales.
SOPHiA GENETICS SA is named as issuer for Ross J. Muken's proposed sale of 9,838 common shares, with an approximate sale date of October 5, 2026. The reported aggregate market value is $79,392.66, and Morgan Stanley Smith Barney LLC is named as broker. The shares were acquired upon vesting of restricted stock units on October 2 and October 3, 2026.
SOPHiA GENETICS SA is the issuer in Officer Philippe Menu’s notice of a proposed sale of 22,394 common shares, with an aggregate market value of $180,719.58 and an approximate sale date of October 5, 2026. The shares were acquired upon vesting of restricted stock units from January 3, 2026 through October 3, 2026. The notice also lists six prior sales identified as 10b5-1 sales, including 5,000 shares on September 14, 2026 and 7,393 shares on July 6, 2026.
SOPHiA GENETICS SA officer Manuela Valente filed a notice for a proposed sale of 4,240 common shares, with an aggregate market value of $34,216.80 and an approximate sale date of October 5, 2026. The securities were acquired through restricted stock unit vesting on October 2 and October 3, 2026. The notice also lists prior 10b5-1 sales during the preceding three months: 10,000 shares for $79,439.00 on August 19, 2026, and 4,241 shares for $21,429.77 on July 6, 2026.
For SOPHiA GENETICS SA (SOPH), Officer George Cardoza filed notice of a proposed sale of 1,592 common shares, with an aggregate market value of $12,847.44. The securities-to-be-sold entry lists Restricted Stock Units as the acquisition type and the issuer as the source. It also lists two prior sales under a Rule 10b5-1 plan: 774 shares on September 21, 2026, for $6,447.42, and 1,592 shares on July 6, 2026, for $8,419.45.
SOPHiA GENETICS SA common shares are the subject of Jurgi Camblong’s Rule 144 notice, which lists a proposed sale of 65,672 shares with an aggregate market value of $529,973.04 and an anticipated sale date of October 5, 2026. The shares include 40,172 shares tied to restricted stock units that vested on October 2 and October 3, 2026, and 25,500 founder shares listed with an acquisition date of March 18, 2021. The sale information names Morgan Stanley Smith Barney LLC and Nasdaq, and lists 85,127,825 shares outstanding. The preceding-three-months table also lists earlier transactions as 10b5-1 sales.
SOPHiA GENETICS SA (SOPH) reported that Chief Financial Officer George Cardoza sold 774 ordinary shares on September 21, 2026 at $8.33 per share, leaving him with 308,318 shares held directly. The footnote states these shares were sold in the open market solely to cover tax withholding obligations from restricted stock units that vested on September 18, 2026, under a pre-established Rule 10b5-1(c) trading plan, and that the trades were not discretionary.